top of page
katelyn-greer-7cWgkwIXGh0-unsplash.jpg

Innovative Diagnostic Tools for Severe Eye Diseases

Multiplex Tests for Early Diagnosis, Prognosis, Treatment Monitoring

What We Do

ExOcular Dx is revolutionizing the management of severe eye diseases. We're developing a robust portfolio of multiplex tests built on innovative exosome-based, disease-specific biomarker analysis. These tests provide precise, early, and actionable insights, paving the way for personalized and transformative patient care. We empower physicians with unparalleled insights to deliver earlier, more effective treatments.

Our Innovative Technology Platform

ExOcular tests isolate exosomes and measure eye disease-specific biomarkers. Our multiplex panels provide physicians and eye care providers with insights into a patient's risk of vision-threatening diseases, facilitate easy tracking of disease progression, and monitor treatment effectiveness.

Asset 48_4x.png

Measure Biomarkers

Multiplex disease-specific biomarkers

exosome.png
Asset 10_4x.png

Inform Care

Is the patient at high risk for vision-threatening disease? Progressing to vision loss? Is treatment effective?

Asset 21_4x.png

Improve Outcomes

Personalize treatment plan.  Reduce unnecessary procedures

Exosomes Make the Difference

Exosomes carry proteins, DNA, and RNA that originate from specific organs and tissues. Their disease-specific cargo evolves with the condition. Their lipid bilayer protects biomarkers from degradation in biofluids, ensuring stability over time. Additionally, biomarkers from exosomes can be much more concentrated as compared to direct blood-based markers, facilitating easier and more reproducible quantification.

The Impact of Severe Eye Disease

The incidence and prevalence of severe eye diseases increase as people age. Our initial focus is on patients with early- to intermediate-stage age-related macular degeneration (AMD) and diabetic retinopathy (DR)— the leading causes of blindness. People older than 50 and diabetic patients may be tested by primary care providers for early detection. Our multiplex biomarker panels assess the risk of progression to vision-threatening disease. For patients with late-stage AMD or DR, our tests help optimize medication dosing, frequency, and personalized treatment.

alpay-tonga-Sp82b8oJYyc-unsplash_edited.jpg

Unmet Clinical Need

ExOcular tests provide physicians with insights into patients at risk for vision-threatening diseases. Our tests enable personalized treatment decisions that may delay or prevent blindness while effectively monitoring intervention success.

Our Solution

market x indications.jpg
Doctor Handshake Patient

For Clinicians

More about ExOcular patient management

For Drug Developers

More about leveraging quantitative biomarker panels in clinical trials
Lab Work

Join Our Team

We're on the hunt for passionate scientists, meticulous laboratorians, and seasoned business professionals to fuel our growth! Join us in doing what you love while making a real difference in the lives of those battling severe eye diseases and the caregivers who support them.

bottom of page